Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Reports Q2 revenue $7.1B, consensus $6.96B. Biktarvy sales increased 9% y/y to $3.5B. “This was a very successful second quarter for Gilead ...

Adjusted earnings per share (EPS) of $2.01 beat the Zacks Consensus Estimate of $1.95 and remained flat year over year.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

GSK has challenged Gilead's HIV behemoth Biktarvy, presenting data that its competing therapy Dovato is equally effective and associated with less weight gain.